Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Business Wire•04/11/2026•07:00 ET
0
Key Highlights
- ➤Signatera-positive patients saw 35% absolute reduction in 2-year locoregional recurrence
- ➤Serial surveillance testing achieved 95.2% sensitivity and 99.4% negative predictive value
- ➤Signatera detected recurrence median 4.3 months before radiographic progression
- ➤Signatera achieved 100% sensitivity in HPV-positive patients
- ➤Signatera-positivity independently predicted progression-free survival over clinical factors
Expert Statements
Michael Krainock, Medical Director, Oncology, Natera
“Head and neck cancer is difficult to treat and carries high recurrence rates, underscoring the importance of catching relapse as early as possible”
Michael Krainock, Medical Director, Oncology, Natera
“Collectively, these new studies demonstrate Signatera’s ability to detect recurrence well in advance of clinical signs and predict which patients were likely to benefit from adjuvant chemotherapy.”
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Findings show Signatera’s predictive and prognostic abilities in a cancer that carries recurrence rates of up to 60%, along with excellent performance of the test in both HPV-positive and HPV-negative subtypes
Get started
Create a free account to read the full story.